Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Next Previous
Trial Profile

A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADCV 01 (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Ever Supreme Bio Technology

Most Recent Events

  • 24 Sep 2026 Planned End Date changed from 30 Dec 2026 to 30 Dec 2027.
  • 24 Sep 2026 Planned primary completion date changed from 30 Dec 2026 to 30 Dec 2027.
  • 13 Sep 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top